EICHORPublic-registry site landscape for NCT05507216, “ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2”, a Ulcerative Colitis study sponsored by Abivax S.A.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05507216 (registry record) |
| Study title | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis |
| Sponsor | Abivax S.A. |
| Condition(s) | Ulcerative Colitis |
| Phase | PHASE3 |
| Listed sites | 273 |
| Site countries | United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia, Czechia, France, Germany, Hungary, India |
Patient-friendly overview of this study: eichor.com/study/NCT05507216.
Eichor generates a preliminary site-risk snapshot for NCT05507216 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Ulcerative Colitis trials
← Eichor home · All tracked trials · Ulcerative Colitis studies · Weekly briefs
